Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Medivation, Inc.; Astellas Pharma US, Inc.
-- As men live longer with disease, survey findings suggest patients and caregivers need increased opportunities for open dialogue and more comprehensive support --
NORTHBROOK, Ill. and SAN FRANCISCO, Sept. 26, 2013 /PRNewswire/ -- Astellas Pharma US, Inc. (TSE: 4503) and Medivation, Inc. (Nasdaq: MDVN) today announced results of a national survey of men with advanced prostate cancer and caregivers of men with advanced prostate cancer.[i] Results showed that while patients who participated in the survey are generally optimistic, a good number may feel isolated in coping with their disease. Forty-five percent reported they keep silent about their prostate cancer and treatments, and 59 percent are concerned about becoming a burden to family and friends. By comparison, only 43 percent of patient respondents have the same level of concern about dying.
Caregivers who participated in the survey expressed a high degree of stress associated with their roles. Nearly three-quarters (73 percent) said there are days when they feel overwhelmed caring for someone with advanced prostate cancer and 85 percent said they experience stress or anxiety related to their loved one's well-being. However, caregiver respondents are more concerned about helping their loved one cope with the physical and emotional effects of advanced disease (83 percent) than they are about their own physical or emotional health (58 percent).
Astellas Pharma US, Inc. and Medivation, Inc. commissioned the Advanced Prostate Cancer Patient and Caregiver Burden of Illness Survey through Harris Interactive, and sponsored four leading cancer advocacy and education organizations to collaborate on the initiative: The Association of Oncology Social Work (AOSW), CancerCare, Prostate Health Education Network (PHEN), and Us TOO Prostate Cancer Education and Support Network. The survey was conducted online among 91 men with advanced prostate cancer and 100 caregivers of such men, and was designed to evaluate the physical and emotional impact of advanced prostate cancer on both patients and caregivers.
"Little, if any, research has been completed to understand the current experience of U.S. men living with advanced prostate cancer or caregivers to these men," said Thomas A. Farrington, founder and president of PHEN. "This survey provides much-needed information that will help us better support them, particularly as there is evidence that men are now living longer with advanced disease."
More than 50 percent of patients who participated in the survey have been living with a prostate cancer diagnosis for at least six years. Nearly one-third of survey respondents (33 percent) reported living with a diagnosis for more than 10 years and 17 percent said they are currently living with another cancer diagnosis in addition to prostate cancer.
Caregiver respondents reported an average caregiving duration of nearly five years. Sixteen percent have been providing care for more than eight years.
Key findings from patients who participated in the survey reveal:
Caregiver participants expressed considerable stress and anxiety, as well as a desire for more direct support networks. Key findings include:
Survey findings also suggest that many patient and caregiver respondents are overwhelmed by the volume of information available to them. About one-third (35 percent) of patients said there is too much information available about prostate cancer to understand it all, and 47 percent of caregivers agreed with this statement. These findings suggest the need for navigation tools that will help guide patients and caregivers to the information that is most relevant to them over the course of the disease.
The American Cancer Society estimates that one in six U.S. men will be diagnosed with prostate cancer in their lifetime and about 2.5 million are currently living with the disease.[ii], Recent studies and analyses have demonstrated that men with advanced prostate cancer are now living longer than ever.[iii],[iv] A 2013 study concluded, "The initial impact of treatments for men with [prostate cancer] is well reported in the literature. Less is known about the psychosocial needs of these men as their journey after diagnosis and treatment continues into months and years."[v]
About the Advanced Prostate Cancer Patient and Caregiver Burden of Illness Survey
The Advanced Prostate Cancer Patient and Caregiver Burden of Illness Study was conducted online within the United States by Harris Interactive on behalf of Astellas Pharma US, Inc. and Medivation, Inc. between August 29, 2012 and March 15, 2013. A total of 91 men age 60+ diagnosed with prostate cancer who have been or are being treated with at least one course of hormone therapy and experienced continued disease progression (i.e., castration-resistant prostate cancer [CRPC]) completed the survey. Simultaneously, Harris Interactive surveyed 100 caregivers of similarly described patients, defined as anyone in regular contact with qualified patients who assist with their care and/or help them make treatment decisions.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. For more information, please visit us at www.medivation.com.
Astellas Pharma US, Inc., located in Northbrook, Illinois, is a US affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. For more information about Astellas Pharma US, Inc., please visit our website at www.Astellas.us.
[i] For the purposes of this survey "advanced" disease was defined as prostate cancer that has been or is are being treated with at least one course of hormone therapy and has continued to progress (i.e., castration-resistant prostate cancer [CRPC]). "Caregivers" was defined as anyone in regular contact with qualified patients who assist with their care and/or help them make treatment decisions.
[ii] American Cancer Society. What are the key statistics about prostate cancer? Available at http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-key-statistics. Accessed August 5, 2013.
[iii] Omlin, A. et. al. Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. Euro Uro. 64:2. August 2013
[iv] Mukherji, D. et. al. New treatment developments applied to elderly patients with advanced prostate cancer. Can Trtmnt Rev. 39:578-573. 2013.
[v] O'Shaughnessy, PK, et. al. Cancer Nurs. 2013 Jan 25.
* Caution: Small base size; results should only be interpreted as directional in nature.
Image with caption: "Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of Illness Survey." Image available at: http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-a
Image with caption: "Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of Illness Survey." Image available at: http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-b
Image with caption: "Findings from The Advanced Prostate Cancer Patient and Caregiver Burden of Illness Survey." Image available at: http://photos.prnewswire.com/prnh/20130926/MM86689-INFO-c
Image with caption: "Astellas Pharma US, Inc. Logo." Image available at: http://photos.prnewswire.com/prnh/20130926/MM86689LOGO-d
Image with caption: "Medivation, Inc. Logo." Image available at: http://photos.prnewswire.com/prnh/20130926/MM86689LOGO-e
©2012 PR Newswire. All Rights Reserved.